DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer
Authors
Mateo, JSandhu, S
Miranda, S
Carreira, S
Jain, S
Ralph, C
Protheroe, A
Hussain, S
Jones, R
Elliott, Tony
McGovern, U
Gillman, A
Paulding, C
Mossop, H
Porta, N
Bianchini, D
Zafeiriou, Z
Boysen, G
Nava Rodrigues, D
Flohr, P
Seed, G
Goodall, J
Figueiredo, I
Perez-Lopez, R
Tunariu, N
Omlin, A
Ferraldeschi, R
Kunju, Lakshmi P
Eeles, R
Attard, G
Robinson, D
Chinnaiyan, A
Hall, E
de Bono, J
Affiliation
The Institute of Cancer Research & The Royal Marsden NHS Trust, LondonIssue Date
2015-08-02
Metadata
Show full item recordCitation
Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer 2015, 75 (15 Supplement):CT322 Cancer ResJournal
Cancer ResearchDOI
10.1158/1538-7445.AM2015-CT322Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2015-CT322